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ABSTRACT
Introduction There is an increasing body of evidence 
to suggest that visibility of prostate cancer on magnetic 
resonance (MRI) may be related to likelihood of adverse 
pathological outcomes. Biochemical recurrence (BCR) 
after radical prostatectomy remains a significant clinical 
challenge and a means of predicting likelihood of this 
prior to surgery could inform treatment choice. It appears 
that MRI could be a potential candidate strategy for BCR 
prediction, and as such, there is a need to review extant 
literature on the prognostic capability of MRI. Here, we 
describe a protocol for a systematic review and meta- 
analysis of the utility of biparametric MRI (bpMRI) and 
multiparametric MRI (mpMRI) in predicting BCR following 
radical prostatectomy for prostate cancer treatment.
Methods and analysis PubMed, MEDLINE, Embase and 
Cochrane databases will be searched and screening will 
be guided by the Preferred Reporting Items for Systematic 
Reviews and Meta- analyses (PRISMA) guidelines. In 
order to meet the inclusion criteria, papers must be 
English- language articles involving patients who have 
had bpMRI or mpMRI for suspected prostate cancer 
and have undergone radical prostatectomy as definitive 
therapy. Patients must have had prostate- specific antigen 
monitoring before and after surgery. All relevant papers 
published from July 1977 to October 2020 will be eligible 
for inclusion. The Newcastle- Ottawa score will be used to 
determine the quality and bias of the studies. This protocol 
is written in- line with the PRISMA protocol 2015 checklist.
Ethics and dissemination There are no relevant ethical 
concerns. Dissemination of this protocol will be via peer- 
reviewed journals as well as national and international 
conferences.
PROSPERO registration number CRD42020206074.
BACKGROUND
Prostate cancer is a one of the leading causes of 
cancer mortality in men worldwide, with over 
a million new cases diagnosed in 2018 alone.1 
Radical prostatectomy is the most commonly 
employed definitive treatment for patients 
with this disease,2 often yielding favourable 
oncological outcomes.3 However, biochem-
ical recurrence (BCR), taken to be a serum 
prostate specific antigen (PSA) level greater 
than or equal to 0.2 ng/dL on two consecutive 
occasions4 occurs in approximately 15%–40% 
of patients.5 6 Prognostically, BCR has high 
utility and is associated with increased inci-
dence of metastatic disease.4 7 It follows then 
that a reliable approach to predicting BCR 
could inform therapeutic decision making.8 
Several models have been proposed for 
prognostication of BCR following radical 
prostatectomy,9–12 however, these have been 
Strengths and limitations of this study
 ► This study will be the first comprehensive system-
atic review and meta- analysis of the utility of bi-
parametric MRI (bpMRI) and multiparametric MRI in 
the prediction of biochemical recurrence following 
radical prostatectomy, written in- line with Preferred 
Reporting Items for Systematic Reviews and Meta- 
analyses guidelines.
 ► This study will employ robust statistical methods to 
minimise the effect of heterogeneity in the literature 
on the determined results.
 ► Heterogeneity of study cohorts may limit the strength 
of conclusions drawn.
 ► Due to limited number of studies which make use of 
bpMRI, there is likely to be a less extensive analysis 
of the prognostic utility of this modality.
 ► Also, due to the relatively recent introduction of 
prostatic MRI scans, there is limited long- term data 
on the clinical outcomes associated with MRI.
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criticised for apparent inaccuracy and inapplicability to 
certain clinical settings.13 14 This highlights the need for a 
widely acceptable and accessible means of understanding 
prostate cancer prognosis in this patient group.
MRI has increasingly become an integral part of pros-
tate cancer screening and diagnosis. In recent years, 
evidence has emerged on the utility of multiparametric 
MRI (mpMRI) in predicting adverse pathology with 
MRI- invisible tumours suggesting a good prognosis and 
MRI- visible tumours associated with unfavourable clinical 
outcomes such as extracapsular extension and seminal 
vesicle invasion.15–18 Given that these pathological factors 
are also associated with increased likelihood of BCR,9 10 
it has been suggested that mpMRI may have a role in the 
prediction of BCR after radical prostatectomy.19 20 This is 
also supported by studies that show that the visibility of 
prostate tumours on mpMRI may corelate with genetic 
markers of poor clinical outcome.21 Biparametric MRI 
(bpMRI) has been considered as a potential alternative 
to mpMRI.22 Although its diagnostic utility is still being 
appraised, there is a growing interest in this modality 
as it has been suggested that it could reduce costs and 
imaging times.23 24 Further exploration of the role of MRI 
in predicting BCR after radical prostatectomy is necessary 
as its use in this way could enhance and improve existing 
models of prostate cancer prognosis, allowing for better 
clinical decision making and patient care.
The aim of this systematic review is to evaluate and 
collate the existing literature on the prognostication 
of BCR after radical prostatectomy using pretreatment 
bpMRI or mpMRI. This will be the first of its kind and it 
will assess the utility of preoperative MRI as a risk stratifi-
cation tool and predictor of long- term clinical outcomes.
METHODS AND ANALYSIS
This protocol for this systematic review has been written 
in compliance with the guidance set out in the Preferred 
Reporting Items for Systematic Reviews and Meta- analyses 
(PRISMA)- Protocols 2015 checklist.25 Included studies 
will undergo thorough appraisal and analysis to reveal the 
extent to which preoperative MRI status results may be 
indicative of the likelihood to develop BCR after radical 
prostatectomy.
Search methodology
Searches will be performed on the PubMed, MEDLINE, 
Embase and Cochrane databases to identify all potentially 
relevant studies published from July 1977 (date of first 
human MRI)26 to October 2020. Free text searches and 
Medical Subject Headings terms will be used with suit-
able Boolean operators. The use of search terms such as 
‘prostate,’ ‘cancer,’ ‘bpMRI’ and ‘mpMRI,’ along with 
alternative terms for ‘BCR,’ ‘radical prostatectomy’ and 
‘prognosis’ will ensure a comprehensive approach. Three 
reviewers will be involved in article selection and evalua-
tion and will employ the use Rayyan, a systematic review 
collaboration tool to improve ease of collaboration, 
screening of studies and removal of duplicates. To mini-
mise likelihood of overlooking relevant literature, refer-
ence lists for each article will be manually screened and 
experts in the field will be approached.
Study selection and data extraction
Studies will be screened by three separate reviewers using 
their title and abstract. Following this, the full- text arti-
cles will then be scrutinised against the inclusion criteria. 
Any disagreements will be resolved by consensus. Exclu-
sions will be documented with the reasons for each case, 
allowing generation of the PRISMA flow chart.
Inclusion criteria
To be selected for this review, studies must involve 
patients with suspected prostate cancer who have under-
gone a pretreatment bpMRI or mpMRI, and both prerad-
ical and postradical prostatectomy serum PSA testing. 
Only studies which use grades of conspicuity (eg, Pros-
tate Imaging- Reporting and Data System, PI- RADS, Likert 
scale, etc) to assess the relationship between MRI visibility 
and BCR will be included.
Exclusion criteria
Case reports, expert opinions, conference abstracts, 
reviews and non- English language articles will be ineli-
gible for inclusion. Studies with patient cohorts who have 
received treatment prior to surgery will also be excluded.
Data extraction
After selection, all articles will meticulously read and 
examined, with relevant data points extracted and 
inputted onto a group spreadsheet. Three or more inde-
pendent reviewers will confirm the data and check for 
accuracy. Collation of data will be carried out as described 
by our group previously.27 The data to be collected is 
summarised in table 1.
Endpoints
The main endpoint of this review will be the identifica-
tion of significant differences in effect estimates such as 
HRs for BCR between MRI- visible (eg, PI- RADS 3–5) and 
MRI- invisible (eg, PI- RADS 1–2) groups. Cancer- specific 
and all- cause mortality will be the secondary endpoints. 
Moderator variables, such as MRI scoring systems (eg, 
PI- RADS vs Likert) and MRI scanner power will be 
compared, and any which are of a notable impact to the 
final summary estimate will be recorded.
Risk of bias in individual studies
The bias and quality of the included studies will be assessed 
by three independent reviewers using the Newcastle- 
Ottawa score. The three sections of this system (selection, 
comparability and outcome) will allow for an evaluation of 
the methods and assessment of the quality of each study. 
The outcome of which will aid in the thematic synthesis. 
Any disagreements between the reviewers will be resolved 
by consensus. In the case that a study is found to be at risk 
of significant bias or is of unsatisfactory standard, it may 
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be excluded. If the study is still deemed fit to be included 
in the analysis, this will be duly noted as a limitation in 
the discussion and conclusion portions of the systematic 
review. As previously described by us elsewhere,28 sections 
of the Newcastle- Ottawa scoring system may be modified 
to better suit the subject area of this review and ensure 
a greater accuracy in the findings. Risk of bias score 
will be assessed as a potential moderator variable in the 
meta- analysis.
Meta-analysis
HRs of BCR from univariate Cox regression analyses of 
MRI visibility groups will be used to create the summary 
estimate for the meta- analysis. Studies which have incor-
porated hazard ratios for MRI visibility into multivari-
able models will not be included in the meta- analysis 
unless the univariate data is available. The distribution 
of untransformed, logit and double- arcsine transformed 
ratios will be compared and will be assessed for normality 
using density plots and tested using the Shapiro- Wilk test. 
Whichever set of ratios most resemble a normal distribu-
tion will be used for further analysis. Interstudy variation 
will be quantified using I² and a random effects model 
will be fitted for estimation the summary estimate. After 
fitting a model to all relevant studies, leave- one- out anal-
yses (LOO) and accompanying diagnostic plots would be 
used to identify influential studies including: externally 
studentised residuals, difference in fits values, Cook’s 
distances, covariance ratios, LOO estimates of the amount 
of heterogeneity, LOO values of the test statistics for 
heterogeneity, hat values and weights. Each study would 
be removed one at a time, and the summary propor-
tion would be re- estimated based on the remaining n-1 
studies. Studies with a statistically significant influence on 
the fitted model would be removed as outliers and the 
model refitted. Finally, a summary estimate comprising 
the remaining studies will be calculated to estimate the 
true hazard associated with MRI visibility or the inverse, 
an MRI invisibility. Subgroup analyses are planned 
between Likert and PI- RADS scoring systems. Data collec-
tion items 1, 4, 7, 8, 9, 10, 11 and 12 will be tested as 
potential moderators assuming a sufficient number of 
studies are present within each group. All data analyses 
and visualisation will be performed using the R statistical 
environment (V.3.6.1, 2019-07-05) using the ‘metafor’ 
and ‘meta’ packages.
Patient and public involvement
No patients were involved in this study.
DISCUSSION
There is an increasing need to risk stratify prostate cancers, 
to accurately identify disease that is more likely to take an 
adverse clinical course.1 29 This systematic review aims to 
address this by appraising current evidence on whether 
tumour MRI visibility is related to BCR of prostate cancer 
after radical prostatectomy, therefore evaluating the 
potential use of bpMRI and mpMRI as risk stratification 
tools in this population.
Current evidence suggests an association between visi-
bility of prostate cancer on MRI with Gleason grade and 
tumour size.30 31 Furthermore, it appears that MRI conspi-
cuity is positively correlated with D’Amico risk nomogram 
scores.32 In terms of the prognostic potential of MRI, it 
has been demonstrated that predictive power of MRI may 
extend beyond its relationship with histopathological 
markers of disease progression. Indeed, raised PI- RADS 
scores33 and apparent diffusion coefficient values have 
Table 1 Data collection items
Item no Data title Data type
1 Year of publication Study characteristic
2 Author names Study characteristic
3 Study design Study characteristic
4 Patient population Demographics
5 No of patients Demographics
6 Preoperative MRI status Demographics
7 No of years of radiologist experience Methodology
8 MRI scoring system Methodology
9 MRI scanner power Methodology
10 Definition of tumour visibility Methodology
11 Definition of BCR Methodology
12 Total follow- up time Methodology
13 BCR status Outcome
14 HR of BCR Outcome
BCR, biochemical recurrence; ;HR, hazard ratio; MRI, magnetic resonance imaging; No, number.
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been shown to independently predict the likelihood of 
BCR.34 35
Although there is a clear potential role for bpMRI and 
mpMRI in predicting BCR after radical prostatectomy, 
across studies, there are variations in methodology, such 
as biopsy sampling, definitions of MRI positivity and 
clinically significant prostate cancer. This, together with 
the unavailability of extensive long- term data on MRI 
outcomes may create a limitation in the ability to form 
robust conclusions in this review. Also, due to inexhaustive 
reporting of tumour characteristics, there is often a lack 
of data on features such as tumour volume and clinical 
stage within MRI- invisible and MRI- visible groups. This 
poses a potential difficultly in understanding the effects 
that these factors may have on the determined results of 
the meta- analysis. We hope to address the heterogeneity 
in the literature and encourage a more uniform approach 
to research in this subject area.
In summary, early evidence suggests that bpMRI and 
mpMRI could provide a means to predict BCR of prostate 
cancer after radical prostatectomy. The wide availability of 
MRI and its non- invasive nature makes it an ideal candi-
date for potential BCR risk stratification.36 Our system-
atic review will assess and analyse the available evidence, 
with the aim of providing a holistic view of the literature. 
This will lead to a clearer understanding of the subject, 
which could inform the choice of appropriate therapy in 
patients with prostate cancer.
Trial status
 ► Preliminary searches: started.
 ► Piloting of the selection study process: not started.
 ► Formal screening: not started.
 ► Data extraction: not started.
 ► Risk of bias assessment: not started.
 ► Data analysis: not started.
Draft of search strategy for Medline, Embase, PubMed and 
Cochrane databases
((prostat* NOT prostatitis) AND (“cancer” OR tumo?r* 
OR malignancy*)) AND (“magnetic resonance imaging” 
OR “MRI” OR “mpMRI” OR “multi- parametric magnetic 
resonance imaging” OR “bpMRI” OR “bi- parametric 
magnetic resonance imaging”) AND (“biochemical 
recurrence” OR “BCR” OR “biochemical failure”) AND 
(“radical prostatectomy” OR “surgery”) AND (prognos* 
OR predict*)
Ethics and dissemination
There are no relevant ethical concerns. Dissemination of 
this protocol will be via peer- reviewed journals as well as 
national and international conferences.
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